- Home
- INFY vs ZTS Comparison
INFY vs ZTS Comparison
Compare INFY & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFY
- ZTS
- Stock Information
- Founded
- INFY 1981
- ZTS 1952
- Country
- INFY India
- ZTS United States
- Employees
- INFY N/A
- ZTS N/A
- Industry
- INFY EDP Services
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- INFY Technology
- ZTS Health Care
- Exchange
- INFY Nasdaq
- ZTS Nasdaq
- Market Cap
- INFY 96.0B
- ZTS 80.4B
- IPO Year
- INFY 1999
- ZTS 2013
- Fundamental
- Price
- INFY $21.18
- ZTS $165.86
- Analyst Decision
- INFY Hold
- ZTS Strong Buy
- Analyst Count
- INFY 7
- ZTS 8
- Target Price
- INFY $20.28
- ZTS $215.38
- AVG Volume (30 Days)
- INFY 7.7M
- ZTS 2.7M
- Earning Date
- INFY 01-16-2025
- ZTS 02-13-2025
- Dividend Yield
- INFY 2.76%
- ZTS 1.04%
- EPS Growth
- INFY 11.25
- ZTS 8.38
- EPS
- INFY 0.79
- ZTS 5.32
- Revenue
- INFY $19,112,000,000.00
- ZTS $9,152,000,000.00
- Revenue This Year
- INFY $1.22
- ZTS $9.48
- Revenue Next Year
- INFY $9.39
- ZTS $4.87
- P/E Ratio
- INFY $26.25
- ZTS $31.20
- Revenue Growth
- INFY 3.02
- ZTS 9.33
- 52 Week Low
- INFY $16.04
- ZTS $144.80
- 52 Week High
- INFY $23.63
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- INFY 33.75
- ZTS 46.04
- Support Level
- INFY $22.48
- ZTS $161.58
- Resistance Level
- INFY $22.97
- ZTS $169.78
- Average True Range (ATR)
- INFY 0.39
- ZTS 3.56
- MACD
- INFY -0.14
- ZTS 0.84
- Stochastic Oscillator
- INFY 3.37
- ZTS 57.34
About INFY Infosys Limited
Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.